Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Dermata Therapeutics Inc. Warrant (DRMAW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/20/2025: DRMAW (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit 0% | Avg. Invested days 18 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/20/2025 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) 5782 | Beta 0.57 | 52 Weeks Range 0.01 - 0.03 | Updated Date 06/14/2025 |
52 Weeks Range 0.01 - 0.03 | Updated Date 06/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.16 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -95.9% | Return on Equity (TTM) -206.26% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 4154323 |
Shares Outstanding - | Shares Floating 4154323 | ||
Percent Insiders - | Percent Institutions - |
Analyst Ratings
Rating - | Target Price - | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Dermata Therapeutics Inc. Warrant
Company Overview
History and Background
Dermata Therapeutics, Inc. is a clinical-stage medical dermatology company founded to identify, develop, and commercialize innovative, first-in-class or best-in-class dermatology products.
Core Business Areas
- Medical Dermatology: Focuses on developing and commercializing innovative treatments for common skin conditions.
Leadership and Structure
The leadership team includes individuals with experience in dermatology and pharmaceutical development. The organizational structure is typical of a small clinical-stage biotech, with emphasis on R&D and clinical trials.
Top Products and Market Share
Key Offerings
- DRM02 (Sebacia Microparticles): A novel treatment for acne vulgaris and rosacea. It's a microparticle technology designed to selectively target and shrink sebaceous glands. Market share is currently zero, as it is not yet approved. Key competitors include companies offering existing acne and rosacea treatments like Accutane (isotretinoin), topical retinoids, and antibiotics.
- DRM014: DRM014 is the company's lead product, in clinical development for the treatment of acne. Market share is currently zero, as it is not yet approved. Key competitors include companies offering existing acne treatments like Accutane (isotretinoin), topical retinoids, and antibiotics.
Market Dynamics
Industry Overview
The dermatology market is growing, driven by increased awareness of skin conditions, aging populations, and demand for cosmetic procedures. There is significant competition and innovation in the industry.
Positioning
Dermata is positioned as an innovator in the dermatology space, focusing on novel mechanisms of action for common skin conditions. Its competitive advantage lies in its proprietary microparticle technology and targeted approach.
Total Addressable Market (TAM)
The global dermatology market is estimated to be in the tens of billions of dollars. Dermata is targeting specific segments, such as acne and rosacea, within this larger market. Their potential revenue is linked to efficacy and approval success.
Upturn SWOT Analysis
Strengths
- Novel technology platform (Sebacia Microparticles)
- Targeted treatment approach
- Potential for improved efficacy and safety compared to existing treatments
Weaknesses
- Clinical-stage company with no approved products
- Dependence on successful clinical trial outcomes
- Limited financial resources
- High risk of failure associated with drug development
Opportunities
- Successful clinical trials leading to regulatory approval
- Partnerships with larger pharmaceutical companies
- Expansion into new dermatology indications
- Market need for more effective and safer treatments for acne and rosacea
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from existing and new treatments
- Patent challenges
- Inability to secure financing
Competitors and Market Share
Key Competitors
- BMY
- LLY
- VRX
- AGN
Competitive Landscape
Dermata faces intense competition from established pharmaceutical companies with approved dermatology products and larger marketing budgets. Dermata's competitive advantage hinges on its novel technology.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth is minimal due to the company being in the clinical stage.
Future Projections: Future growth is dependent on successful clinical trials and regulatory approvals. Analyst estimates are highly variable.
Recent Initiatives: Recent initiatives include advancing clinical trials for DRM014 and DRM02.
Summary
Dermata Therapeutics is a high-risk, high-reward clinical-stage company with a novel technology platform. The company's success is heavily reliant on positive clinical trial outcomes and regulatory approvals. While their targeted approach presents a potential advantage, they face strong competition and financial constraints, but if successful would create a large payout. It is essential to watch for clinical results and funding rounds to determine if the warrants provide an opportunity.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Dermata Therapeutics Investor Relations
- SEC Filings
- Industry Reports
- Financial News Outlets
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Investment decisions should be based on individual research and consultation with a financial advisor. Market data is subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Dermata Therapeutics Inc. Warrant
Exchange NASDAQ | Headquaters San Diego, CA, United States | ||
IPO Launch date 2021-08-13 | Founder, President, CEO & Chairman Mr. Gerald T. Proehl | ||
Sector Healthcare | Industry Biotechnology | Full time employees 8 | Website https://www.dermatarx.com |
Full time employees 8 | Website https://www.dermatarx.com | ||
Dermata Therapeutics, Inc., a late-stage medical dermatology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical skin diseases and aesthetic applications. Its lead product candidate is XYNGARI, which is in Phase 3 clinical studies for the treatment of moderate-to-severe acne, as well as completed Phase 1b proof of concept (POC) trial for mild-to-moderate psoriasis. The company is also developing DMT410 that has completed Phase 1b POC trials for the treatment of axillary hyperhidrosis and aesthetic skin conditions. It has a clinical trial collaboration agreement with Revance Therapeutics, Inc. to conduct a multi-center clinical trial to evaluate the topical application of XYNGARI with DAXXIFY, Revance's botulinum toxin type A. Dermata Therapeutics, Inc. was incorporated in 2014 and is headquartered in San Diego, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.